The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...
Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. You’re listening to our weekly science news roundup. Let’s start off with a vaccine 180.
The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...
Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...
The Food and Drug Administration reversed course on Wednesday and agreed to formally review Moderna’s new flu vaccine that uses mRNA technology, the company announced in a news release. Earlier this ...
Shares of Moderna surged Wednesday after the drugmaker got health regulators to change their minds and start reviewing the biotechnology company’s flu-vaccine candidate for potential approval. The ...
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...
Moderna said Wednesday the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling ...
The Food and Drug Administration has reversed its shocking refusal to consider Moderna’s mRNA flu vaccine for approval. The refusal was revealed last week in a sharply worded press release from ...
The FDA has agreed to review Moderna’s investigational flu vaccine for potential approval, about a week after telling the drugmaker it would not consider the application. On Feb. 10, the agency ...
Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...
The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results